Health Care & Life Sciences » Biotechnology | Calithera Biosciences Inc.

Calithera Biosciences Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
33,820.00
101,969.00
69,928.00
51,781.00
163,793.00
136,153
Total Accounts Receivable
-
-
-
-
1,142.00
1,997
Other Current Assets
349.00
1,894.00
2,567.00
1,780.00
2,732.00
2,102
Total Current Assets
34,169.00
103,863.00
72,495.00
53,561.00
167,667.00
140,252
Net Property, Plant & Equipment
559.00
861.00
931.00
899.00
1,759.00
1,464
Total Investments and Advances
116.00
46.00
2,043.00
46.00
22,801.00
440
Other Assets
-
-
281.00
290.00
228.00
569
Total Assets
34,844.00
104,770.00
75,750.00
54,796.00
192,455.00
142,725
Accounts Payable
-
-
-
-
1,072.00
Other Current Liabilities
1,344.00
4,121.00
3,833.00
4,453.00
37,955.00
Total Current Liabilities
1,344.00
4,121.00
3,833.00
4,453.00
39,027.00
Other Liabilities
31.00
283.00
129.00
437.00
3,121.00
Total Liabilities
1,375.00
4,404.00
3,962.00
4,890.00
42,148.00
Common Equity (Total)
20,813.00
100,366.00
71,788.00
49,906.00
150,307.00
Total Shareholders' Equity
33,469.00
100,366.00
71,788.00
49,906.00
150,307.00
Total Equity
33,469.00
100,366.00
71,788.00
49,906.00
150,307.00
Liabilities & Shareholders' Equity
34,844.00
104,770.00
75,750.00
54,796.00
192,455.00
Preferred Stock (Carrying Value)
54,282.00
-
-
-
-

About Calithera Biosciences

View Profile
Address
343 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.calithera.com
Updated 07/08/2019
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A.